Therapy of chronic hepatitis B: focus on telbivudine

被引：8

作者：

Gaeta, Giovanni Battista ^{[1
]}

Stornaiuolo, Gianfranca ^{[1
]}

机构：

[1] Univ Naples 2, Acute & Chron Hepatitis Unit, Naples, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2007年 / 39卷

关键词：

chronic hepatitis B; interferon; necroinflammation; telbivudine;

D O I：

10.1016/S1590-8658(07)60017-6

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Hepatitis B virus (HBV) viral load is closely related to necroinflammation and the outcome of chronic hepatitis B. The available treatment options to reduce viral load, and hence improve outcome, are either based on IFN or on nucleoside/nucleotide analogue antiviral agents, which inhibit HBV DNA replication. Use of IFN alfa or pegylated IFN alfa-2a for periods longer than 48 weeks is limited by their side-effects. The antiviral agents have much more acceptable side-effect profiles, and lamivudine, the first antiviral to become available, was widely used until it became apparent that it carries a high potential for resistance to emerge, which rapidly negates its benefit. A new antiviral agent, telbivudine, has been approved in the USA and Europe and appears to be very rapid and potent against HBV, with an excellent safety profile. (C) 2007 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

引用

页码：S372 / S378

页数：7

共 29 条

[1]

BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO

[2]

2-J

[3] Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study [J].

Brunetto, MR ;

Oliveri, F ;

Coco, B ;

Leandro, G ;

Colombatto, P ;

Gorin, JM ;

Bonino, F .

JOURNAL OF HEPATOLOGY, 2002, 36 (02) :263-270

[4] Antiviral L-nucleosides specific for hepatitis B virus infection [J].

Bryant, ML ;

Bridges, EG ;

Placidi, L ;

Faraj, A ;

Loi, AG ;

Pierra, C ;

Dukhan, D ;

Gosselin, G ;

Imbach, JL ;

Hernandez, B ;

Juodawlkis, A ;

Tennant, B ;

Korba, B ;

Cote, P ;

Marion, P ;

Cretton-Scott, E ;

Schinazi, RF ;

Sommadossi, JP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :229-235

[5]

Bzowej N, 2006, HEPATOLOGY, V44, p563A

[6] A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B [J].

Chang, TT ;

Gish, RG ;

de Man, R ;

Gadano, A ;

Sollano, J ;

Chao, YC ;

Lok, AS ;

Han, KH ;

Goodman, Z ;

Zhu, J ;

Cross, A ;

DeHertogh, D ;

Wilber, R ;

Colonno, R ;

Apelian, D .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1001-1010

[7] Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].

Chen, CJ ;

Yang, HI ;

Su, J ;

Jen, CL ;

You, SL ;

Lu, SN ;

Huang, GT ;

Iloeje, UH .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73

[8] Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine [J].

Di Marco, V ;

Marzano, A ;

Lampertico, P ;

Andreone, P ;

Santantonio, T ;

Ahnasio, PL ;

Rizzetto, M ;

Craxì, A .

HEPATOLOGY, 2004, 40 (04) :883-891

[9]

DiBisceglie A, 2006, HEPATOLOGY, V44, p230A

[10] Mechanisms of disease: Hepatitis B virus infection - Natural history and clinical consequences [J].

Ganem, D ;

Prince, AM .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) :1118-1129

← 1 2 3 →